Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 3M | 2M | 2M | 1M |
| Gross Profit | 3M | 2M | 2M | 1M |
| Operating Income | -160M | -78M | -40M | -24M |
| EBITDA | -160M | -78M | -40M | -24M |
| Net Income | -143M | -63M | -21M | -24M |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$6.25
+1.63% today
1Y Change
-44.78%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Upstream Bio, Inc. (UPB) is a Healthcare stock with a market cap of $510.00M and listed on NASDAQ. The stock last traded around $6.25 and down 44.8% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +20.4%, EPS growth of -78.5%, a dividend yield of 0.0%. What stands out right now is revenue +20.4%, EPS -78.5%, free cash flow -123.3% with operating margin -5618.8% and ROIC -47.0%. Valuation already assumes a fairly strong business story at price/sales 179.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines UPB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UPB
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
UPB Max Drawdown
-81.84%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for UPB and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.2M
-49.1% YoY
FY Net Income
-$23.9M
-16.2% YoY
Free Cash Flow
-$19.1M
+49.8% YoY
Revenue Growth
+20.4%
EPS Growth
-78.5%
Gross Margin
96.9%
Net Margin
-5026.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 3M | 2M | 2M | 1M |
| Gross Profit | 3M | 2M | 2M | 1M |
| Operating Income | -160M | -78M | -40M | -24M |
| EBITDA | -160M | -78M | -40M | -24M |
| Net Income | -143M | -63M | -21M | -24M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & Equivalents | 102M | 326M | 26M | 17M |
| Total Assets | 354M | 482M | 117M | 18M |
| Total Liabilities | 14M | 12M | 240M | 125M |
| Shareholder Equity | 340M | 470M | -123M | -106M |
| Total Debt | 1M | 2M | 45K | 94K |
| Net Debt | -100M | -324M | -26M | -17M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
19M
+49.8% YoY
Capital Expenditures
82K
+43.1% YoY
Free Cash Flow
19M
+49.8% YoY
Key ratios
Gross Margin
96.9%
Operating Margin
-5618.8%
Net Margin
-5026.0%
ROE
-36.5%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.